<DOC>
	<DOCNO>NCT02264171</DOCNO>
	<brief_summary>Study investigate effect CYP3A4 inhibition ketoconazole single oral dose pharmacokinetics tamsulosin investigate effect safety tolerability</brief_summary>
	<brief_title>Study Investigate Effect Ketoconazole Mediated CYP3A4 Inhibition Pharmacokinetics Tamsulosin Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>All participant study Healthy male Ranging 21 50 year age Body mass index ( BMI ) within 18.5 29.9 kg/m2 ( BMI calculation : weight kilogram divide square height meter ) In accordance Good Clinical Practice ( GCP ) local legislation volunteer give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , clinically relevant electrolyte disturbance Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic clinically relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( within two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Any laboratory value outside reference range indicative underlying disease poor health Excessive physical activity within last week trial trial Hypersensitivity treatment medication and/or relate drug class Non extensive metabolizer ( EM ) CYP2D6</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>